These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 23250513)

  • 21. Predictors of acute metabolic decompensation in children with maple syrup urine disease at the emergency department.
    Yıldız Y; Akcan Yıldız L; Dursun A; Tokatlı A; Coşkun T; Tekşam Ö; Sivri HS
    Eur J Pediatr; 2020 Jul; 179(7):1107-1114. PubMed ID: 32048023
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dual mechanism of brain injury and novel treatment strategy in maple syrup urine disease.
    Zinnanti WJ; Lazovic J; Griffin K; Skvorak KJ; Paul HS; Homanics GE; Bewley MC; Cheng KC; Lanoue KF; Flanagan JM
    Brain; 2009 Apr; 132(Pt 4):903-18. PubMed ID: 19293241
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of maple syrup urine disease with high flow hemodialysis in a neonate.
    Aygün F; Kıykım E; Aktuğlu-Zeybek Ç; Zubarioğlu T; Cam H
    Turk J Pediatr; 2019; 61(1):107-110. PubMed ID: 31559730
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Maple syrup urine disease and cystathioninemia].
    Simma B; Sperl W; Berger H
    Padiatr Padol; 1989; 24(1):69-75. PubMed ID: 2497426
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Branched-chain α-ketoacid dehydrogenase deficiency (maple syrup urine disease): Treatment, biomarkers, and outcomes.
    Strauss KA; Carson VJ; Soltys K; Young ME; Bowser LE; Puffenberger EG; Brigatti KW; Williams KB; Robinson DL; Hendrickson C; Beiler K; Taylor CM; Haas-Givler B; Chopko S; Hailey J; Muelly ER; Shellmer DA; Radcliff Z; Rodrigues A; Loeven K; Heaps AD; Mazariegos GV; Morton DH
    Mol Genet Metab; 2020 Mar; 129(3):193-206. PubMed ID: 31980395
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Living related versus deceased donor liver transplantation for maple syrup urine disease.
    Feier F; Schwartz IV; Benkert AR; Seda Neto J; Miura I; Chapchap P; da Fonseca EA; Vieira S; Zanotelli ML; Pinto e Vairo F; Camelo JS; Margutti AV; Mazariegos GV; Puffenberger EG; Strauss KA
    Mol Genet Metab; 2016 Mar; 117(3):336-43. PubMed ID: 26786177
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reduction of large neutral amino acid concentrations in plasma and CSF of patients with maple syrup urine disease during crises.
    Wajner M; Coelho DM; Barschak AG; Araújo PR; Pires RF; Lulhier FL; Vargas CR
    J Inherit Metab Dis; 2000 Jul; 23(5):505-12. PubMed ID: 10947205
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term metabolic follow-up and clinical outcome of 35 patients with maple syrup urine disease.
    Abi-Wardé MT; Roda C; Arnoux JB; Servais A; Habarou F; Brassier A; Pontoizeau C; Barbier V; Bayart M; Leboeuf V; Chadefaux-Vekemans B; Dubois S; Assoun M; Belloche C; Alili JM; Husson MC; Lesage F; Dupic L; Theuil B; Ottolenghi C; de Lonlay P
    J Inherit Metab Dis; 2017 Nov; 40(6):783-792. PubMed ID: 28905140
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Classical maple syrup urine disease and brain development: principles of management and formula design.
    Strauss KA; Wardley B; Robinson D; Hendrickson C; Rider NL; Puffenberger EG; Shellmer D; Moser AB; Morton DH
    Mol Genet Metab; 2010 Apr; 99(4):333-45. PubMed ID: 20061171
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcome of early and long-term management of classical maple syrup urine disease.
    Clow CL; Reade TM; Scriver CR
    Pediatrics; 1981 Dec; 68(6):856-62. PubMed ID: 6798541
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Second-tier test for quantification of alloisoleucine and branched-chain amino acids in dried blood spots to improve newborn screening for maple syrup urine disease (MSUD).
    Oglesbee D; Sanders KA; Lacey JM; Magera MJ; Casetta B; Strauss KA; Tortorelli S; Rinaldo P; Matern D
    Clin Chem; 2008 Mar; 54(3):542-9. PubMed ID: 18178665
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Maple syrup urine disease: branched-chain amino acid concentrations and metabolism in cultured human lymphoblasts.
    Skaper SD; Molden DP; Seegmiller JE
    Biochem Genet; 1976 Aug; 14(7-8):527-39. PubMed ID: 985377
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Brain-blood amino acid correlates following protein restriction in murine maple syrup urine disease.
    Vogel KR; Arning E; Wasek BL; McPherson S; Bottiglieri T; Gibson KM
    Orphanet J Rare Dis; 2014 May; 9():73. PubMed ID: 24886632
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oxidative stress in plasma from maple syrup urine disease patients during treatment.
    Barschak AG; Sitta A; Deon M; Barden AT; Dutra-Filho CS; Wajner M; Vargas CR
    Metab Brain Dis; 2008 Mar; 23(1):71-80. PubMed ID: 18026828
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Maple syrup urine disease: Characteristics of diagnosis and treatment in 45 patients in Chile.
    Medina MF; Castro G; Falcon F; Cabello JF; Faundes V; Ruffato D; Salazar MF; Arias C; Peñaloza F; De La Parra A; Cornejo V
    Am J Med Genet C Semin Med Genet; 2021 Sep; 187(3):373-380. PubMed ID: 34288399
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Compliance of the diet restricted with leucine, isoleucine and valine in maple syrup urine disease (MSUD) children].
    Kowalik A; Narojek L; Sykut-Cegielska J
    Rocz Panstw Zakl Hig; 2007; 58(1):95-101. PubMed ID: 17711097
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Maple syrup urine disease: clinical, EEG, and plasma amino acid correlations with a theoretical mechanism of acute neurotoxicity.
    Korein J; Sansaricq C; Kalmijn M; Honig J; Lange B
    Int J Neurosci; 1994 Nov; 79(1-2):21-45. PubMed ID: 7744549
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Docosahexaenoic acid status in females of reproductive age with maple syrup urine disease.
    Mazer LM; Yi SH; Singh RH
    J Inherit Metab Dis; 2010 Apr; 33(2):121-7. PubMed ID: 20217236
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Imaging findings of anaplastic astrocytoma in a child with maple syrup urine disease: a case report.
    Aw-Zoretic J; Wadhwani NR; Lulla RR; Ryan ME
    Childs Nerv Syst; 2015 Sep; 31(9):1625-9. PubMed ID: 26084772
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Total branched-chain amino acids requirement in patients with maple syrup urine disease by use of indicator amino acid oxidation with L-[1-13C]phenylalanine.
    Riazi R; Rafii M; Clarke JT; Wykes LJ; Ball RO; Pencharz PB
    Am J Physiol Endocrinol Metab; 2004 Jul; 287(1):E142-9. PubMed ID: 14970005
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.